Aminoglycoside dosing weight correction factors for patients of various body sizes.
about
Evaluation of extended interval dosing aminoglycosides in the morbidly obese populationPharmacokinetic Changes and Dosing Modification of Aminoglycosides in Critically Ill Obese Patients: A Literature ReviewDosing of antibacterial agents in obese adults: does one size fit all?Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing.Therapeutic drug monitoring of amikacin in septic patients.Pharmacokinetics of Antimicrobials in Obese Children.Revisiting the loading dose of amikacin for patients with severe sepsis and septic shockPreventing surgical site infections after bariatric surgery: value of perioperative antibiotic regimens.Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.Pharmacokinetics of gentamicin at traditional versus high doses: implications for once-daily aminoglycoside dosing.Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patientsImproving dosing of gentamicin in the obese patient: a 3-cycle drug chart and case note audit.Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.Adjusted body weight, con: why adjust body weight in energy-expenditure calculations?The Prevention of Periprosthetic Joint Infections.Clinical pharmacokinetics and pharmacodynamics of tigecycline.Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options).Recording inpatient weight: implications for medicines administration.A study to evaluate the first dose of gentamicin needed to achieve a peak plasma concentration of 30 mg/l in patients hospitalized for severe sepsis.Population pharmacokinetics of metformin in obese and non-obese patients with type 2 diabetes mellitus.Management of aminoglycosides in the intensive care unit.A dose-ranging study of gentamicin pharmacokinetics: implications for extended interval aminoglycoside therapy.Impact of small-for-gestational age (SGA) status on gentamicin pharmacokinetics in neonates.Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia.Comparative evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) study equation for drug dosing: an opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy.What is the best size predictor for dose in the obese child?Study of relationship between volume of distribution and body weight application to amikacin.Approaches for optimising intravenous iron dosing in pregnancy: a retrospective cohort study.High-dose amikacin for achieving serum target levels in critically ill elderly patients.Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance Across Body Size.Perioperative Antibiotics
P2860
Q29006722-F74025F1-80BC-45CD-A089-85C6FD6B991DQ29248398-441A5370-C133-49F5-B337-5CA3074FC1A1Q30362353-C5ABE6A5-DA1F-4533-A9D5-17996E3AD0E2Q33624977-7EDCD79D-BC11-43C9-A673-09720A8D7B0BQ33754166-5CDBAC62-FE3A-4FB2-80A6-9C0541C8A830Q33855312-310E915C-7928-4347-BFFA-41182873CFEAQ33919190-1DAFF87E-6B04-4DDA-B443-B947982E2F32Q33995500-7634AE6C-94EF-4D2E-A0B3-04FCE1EB153AQ34075909-35867399-DE95-4E09-BE48-EC266A62D2E0Q35136143-1B6971BA-8931-4E7D-8DB8-D1752E9A8804Q35191383-04E6572F-280C-4CAB-8C24-9C37414FDB3DQ36034231-6DE49274-87B3-4E46-9761-1A5DB2D9C98FQ36111191-ACF462EF-4C22-474B-891C-5876B4BC6B0FQ36247129-0B1E09F4-BF07-4B41-B583-EAD3085CCC6AQ36278432-0FFDA08E-4B3C-41A4-A759-84B3E964D116Q37580823-84D4A38E-05FC-40BE-9E17-C03A10063627Q37590845-33A39E11-42A9-4600-BA7E-5EE0160F89AAQ37838126-E734B9B8-D641-4A75-8A10-C151F2DD714AQ38907793-C2407F2E-2AA8-46B8-9532-B25690DF2BFFQ40107546-2E94B689-AC55-4574-B75B-2EE4231D87A9Q40689023-E72DEE73-8417-408B-B71D-5343231D2FECQ42633482-0C41BF7B-6060-4988-AFCC-9FC2A45ECBBDQ42908869-6896C485-9BD5-4579-8780-C193A1108158Q43576827-A994D14D-A8C7-45E2-B4A1-F1763D45E6B3Q44321061-9BEFBE21-4B06-491D-94B8-27F23D676288Q45086694-0B7D6F78-059A-40CA-B54A-0FF8C8EF7384Q45191658-0187DF1A-BEE6-4047-B992-EAE5C6CEAD6CQ47179401-7E2A14B7-1BE6-402B-BAAE-73FD6A999A4CQ47180268-EFE9DACE-1D7D-43B1-9BEE-887F71EDE973Q47871375-AB2A687A-720D-4551-8A7B-C07EA88825B4Q50319655-4596FB49-6EC4-46B9-8B6D-5F583A6681B4Q52381647-C398E8E3-F114-433F-BA05-D208FC77733DQ56928143-92CACB5D-AD08-4567-9186-6155B2359C09
P2860
Aminoglycoside dosing weight correction factors for patients of various body sizes.
description
1995 nî lūn-bûn
@nan
1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Aminoglycoside dosing weight correction factors for patients of various body sizes.
@ast
Aminoglycoside dosing weight correction factors for patients of various body sizes.
@en
type
label
Aminoglycoside dosing weight correction factors for patients of various body sizes.
@ast
Aminoglycoside dosing weight correction factors for patients of various body sizes.
@en
prefLabel
Aminoglycoside dosing weight correction factors for patients of various body sizes.
@ast
Aminoglycoside dosing weight correction factors for patients of various body sizes.
@en
P2093
P2860
P356
P1476
Aminoglycoside dosing weight correction factors for patients of various body sizes.
@en
P2093
Bertino JS Jr
Nafziger AN
Traynor AM
P2860
P304
P356
10.1128/AAC.39.2.545
P407
P577
1995-02-01T00:00:00Z